

WHAT IS CLAIMED IS:

- Sub C17
1. A method of treating cancer in a dog, comprising the step of feeding the dog a therapeutic agent comprising a vitamin D analog.
 2. The method of claim 1, wherein the vitamin D analog is selected from the group consisting of $1\alpha,25-(\text{OH})_2\text{D}_3$, $1\alpha,25-(\text{OH})_2$ -16-ene-23-yne- D_3 (analog V), and $1\alpha,25-(\text{OH})_2$ -22,24-diene-24,26,27-trihomo- D_3 (EB 1089) and stereoisomers thereof.
 3. The method of claim 2, wherein the vitamin D analog is $1\alpha,25-(\text{OH})_2\text{D}_3$ and stereoisomers thereof.
 4. The method of claim 2, wherein the vitamin D analog is $1\alpha,25-(\text{OH})_2$ -16-ene-23-yne- D_3 (analog V) and stereoisomers thereof.
 5. The method of claim 2, wherein the vitamin D analog is $1\alpha,25-(\text{OH})_2$ -22,24-diene-24,26,27-trihomo- D_3 (EB 1089) and stereoisomers thereof.
 6. The method of claim 1, wherein the vitamin D analog is administered in combination with a bone agent, a cytotoxic agent, an immuno response regulating agent, an antiinflammatory agent or combinations thereof.
 7. The method of claim 1 wherein the vitamin D analog is administered orally in encapsulated form in a liquid vehicle ingestible by the dog.
 8. The method of claim 1, wherein the dog is fed from about 0.025 to about 500 nmol/kg of body weight of the patient per day of the vitamin D analog.
 9. The method of claim 8, wherein the dog is fed from about 0.025 to about 100 nmol/kg of body weight of the patient per day of the vitamin D analog.
 10. The method of claim 9, wherein the dog is fed from about 0.025 to about 10 nmol/kg of body weight of the patient per day of the vitamin D analog.

0.01 - 10 $\mu\text{g/day}$

11. The method of claim 9, wherein the dog is fed from about 0.025 to about 1.0 nmol/kg of body weight of the patient per day of the vitamin D analog.

12. The method of claim 1, wherein the dog is fed a therapeutically efficacious dosage of a vitamin D analog.

13. A food for dogs comprising a vitamin D analog.

14. The food of claim 13, wherein the vitamin D analog is selected from the group consisting of $1\alpha,25-(\text{OH})_2\text{D}_3$, $1\alpha,25-(\text{OH})_2$ -16-ene-23-yne- D_3 (analog V), and $1\alpha,25-(\text{OH})_2$ -22,24-diene-24,26,27-trihomo- D_3 (EB 1089) and stereoisomers thereof.

15. The food of claim 13, wherein the vitamin D analog is $1\alpha,25-(\text{OH})_2\text{D}_3$ and stereoisomers thereof.

16. The food of claim 13, wherein the vitamin D analog is $1\alpha,25-(\text{OH})_2$ -16-ene-23-yne- D_3 (analog V) and stereoisomers thereof.

17. The food of claim 13, wherein the vitamin D analog is $1\alpha,25-(\text{OH})_2$ -22,24-diene-24,26,27-trihomo- D_3 (EB 1089) and stereoisomers thereof.

add A₁
add C₂